{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T01:10:22Z","timestamp":1754183422162,"version":"3.41.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Pyoderma gangrenosum (PG) is a rare inflammatory skin disorder, categorised under neutrophilic dermatoses. It can be idiopathic or associated with underlying conditions like inflammatory bowel disease, autoimmune diseases, and certain cancers. Some medications, including tumour necrosis factor-alpha inhibitors like adalimumab, can also induce this paradoxical reaction. We describe the case of a 19-year-old male with adalimumab-induced PG, which was successfully treated with methotrexate, contributing to the understanding of drug-induced PG and alternative treatment strategies.<\/jats:p>","DOI":"10.1093\/mrcr\/rxae073","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T15:35:22Z","timestamp":1733412922000},"source":"Crossref","is-referenced-by-count":0,"title":["Paradoxical pyoderma gangrenosum secondary to adalimumab successfully treated with methotrexate: A case report"],"prefix":"10.1093","volume":"9","author":[{"given":"Kristy","family":"El Morr","sequence":"first","affiliation":[{"name":"Department of Dermatology, Faculty of medicine and medical sciences, University of Balamand , Balamand,","place":["Lebanon"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-2923","authenticated-orcid":false,"given":"Mohamad Ali","family":"Rida","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of medicine and medical sciences, University of Balamand , Balamand,","place":["Lebanon"]},{"name":"Clemenceau Medical Center, Johns Hopkins International , Beirut PO BOX 11-2555,","place":["Lebanon"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"2025080201012830300_R1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma gangrenosum\u2013a guide to diagnosis and management","volume":"19","author":"George","year":"2019","journal-title":"Clin Med"},{"key":"2025080201012830300_R2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.det.2023.12.002","article-title":"Treatment of pyoderma gangrenosum","volume":"42","author":"Tan","year":"2024","journal-title":"Dermatol Clin"},{"key":"2025080201012830300_R3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/iwj.12939","article-title":"Epidemiology of pyoderma gangrenosum: results from an Italian prospective multicentre study","volume":"15","author":"Monari","year":"2018","journal-title":"Int Wound J"},{"key":"2025080201012830300_R4","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1197273","article-title":"Pyoderma gangrenosum following anti-TNF therapy in chronic recurrent multifocal osteomyelitis: drug reaction or cutaneous manifestation of the disease? A critical review on the topic with an emblematic case report","volume":"10","author":"Romagnuolo","year":"2023","journal-title":"Front Med"},{"key":"2025080201012830300_R5","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"2025080201012830300_R6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.07.058","article-title":"44360 adalimumab paradoxically causing pyoderma gangrenosum","volume":"89","author":"Hilton","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025080201012830300_R7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4103\/ijdvl.IJDVL_277_18","article-title":"Adalimumab-induced pyoderma gangrenosum in a patient with hidradenitis suppurativa: a paradoxical reaction","volume":"85","author":"Company-Quiroga","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2025080201012830300_R8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jdcr.2016.11.006","article-title":"Pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH) syndrome with recurrent vasculitis","volume":"3","author":"Niv","year":"2017","journal-title":"JAAD Case Rep"},{"key":"2025080201012830300_R9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2025080201012830300_R10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jaad.2023.10.063","article-title":"Methotrexate for pyoderma gangrenosum: a retrospective case series of 33 patients","volume":"90","author":"Williams","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxae073\/61214602\/rxae073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxae073\/61214602\/rxae073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxae073\/61214602\/rxae073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:01:41Z","timestamp":1754110901000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxae073\/7919247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxae073","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2024,12,9]]},"article-number":"rxae073"}}